As shown in Fig. 4A, diffuse large B-cell lymphoma had the highest frequency of MeCP2 alterations, including amplification and deep deletion (> 10%), followed by stomach adenocarcinoma (> 6%) and uterine corpus endometrial carcinoma (> 6%). Here, MECP2 is linked to gastric adenocarcinoma.